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ABSTRACT
Previous studies showed that binding of the CBF/
NF-Y (CBF) transcription factor to cellular promoters
is essential for cell proliferation. This observation
prompted us to investigate the function of CBF in
relation to cell cycle progression and in cell-cycle-
regulated transcription. In this study, we used a
tetracycline-inducible adenoviral vector to express a
truncated CBF-B subunit, Bdbd, lacking a transcrip-
tion activation domain in various mammalian cell
lines. The Bdbd polypeptide interacts with cellular
CBF-A/CBF-C and binds to promoters containing
CBF-binding sites. Interestingly, expression of Bdbd
in various mammalian cells resulted in the inhibition
of cell proliferation and specific cell cycle arrest
at G2/M phase. Gene expression analysis demons-
trated that the expression of Bdbd strongly suppres-
sed cell cycle-dependent transcription activation of
Cyclin B1, Aurora A and CDK1 genes, key regu-
lators for cell cycle progression at G2/M phase.
Chromatin immunoprecipitation analysis showed
that Bdbd significantly inhibited binding of TATA-
binding protein, TBP to both Cyclin B1 and Aurora A
promoters, but did not inhibit binding of E2F3
activator to Cyclin B1 promoter. This study sugges-
ted that the activation domain of CBF-B plays an
essential role in the transcription activation of
Cyclin B1 and Aurora A genes at G2/M phase, thus
regulating cell cycle progression at G2/M phase.
INTRODUCTION
In mammalian cells, transcription of several genes including
Cyclin B1, CDK1 (also known as CDC2) and Aurora A is
activated at G2/M phase of the cell cycle. The proteins
encoded by these genes play crucial roles in progression
through mitosis. Inhibition of the activity of any of these
proteins often leads to arrest of cells at G2/M phase (1–4).
Thus, coordinated transcription activation of these genes is
believed to be essential for cell cycle progression at G2/M
phase. Also, expression of both Cyclin B1 and Aurora A
genes is increased in various human tumors (5,6).
Previous studies of Cyclin B1, CDK1, CDC25C and
topoisomerase IIa promoters showed that binding of the
CBF/NF-Y (CBF) transcription factor to these promoters
plays a crucial role in transcription activation of them at
G2/M phase (2,7–9). Comparative genomic analysis identiﬁed
a conserved regulatory promoter module consisting of a
CBF-binding site, a cell cycle-dependent element (CDE)
and a cell cycle homology region (CHR). The proposed
module is present in different human genes that are activated
at G2/M phase. This suggested that CBF controls trans-
cription of multiple genes at G2/M phase (10,11).
Mammalian CBF consists of three subunits, CBF-A
(NF-YB), CBF-B (NF-YA) and CBF-C (NF-YC), which are
all needed for DNA binding (12,13). CBF consists of two
transcription activation domains: one each in CBF-B and
CBF-C. Interestingly, the activity of CBF-B is regulated by
cyclin-dependent kinase 2 (CDK2) phosphorylation. Muta-
tion of CBF-B that inhibits CDK2-dependent phosphorylation
has been shown to decrease DNA binding of CBF (14). This
study suggested that phosphorylation of CBF-B plays a role
in the transcription activation of genes at G2/M phase. The
tumor suppressor protein p53 inhibits transcription activation
of Cyclin B1, CDK1, securin and topoisomerase IIa promo-
ters through CBF-binding sites. Recent studies showed that
p53 inhibits CBF activity through inhibition of CDK2-
dependent phosphorylation as well as through direct interac-
tion with CBF (8,14–18). Altogether these studies indicated
that CBF-binding sites in the G2/M speciﬁc promoters are
needed for transcription activation as well as for transcription
repression.
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studied by the expression of dominant-negative CBF-B
mutants and also by conditional inactivation of the mouse
CBF-B gene (19–21). When a dominant-negative CBF-B
mutant that interacted with CBF-A/CBF-C but did not bind
DNA was expressed in mouse ﬁbroblasts, this resulted in
the retardation of cell growth. Similarly, expression of a
CBF-B mutant defective in CDK2-dependent phosphoryla-
tion resulted in inhibition of the proliferation of human
colorectal cancer cells. Further analysis of the cells showed
that the growth arrest occurred at both G1/S and G2/M. Inac-
tivation of the CBF-B gene in mouse embryonic ﬁbroblasts
also resulted in complete inhibition of cell proliferation and
growth arrest at various phases of the cell cycle. Taken
together, these studies demonstrated that inhibition of DNA
binding by CBF leads to growth arrest at multiple phases of
the cell cycle.
Since previous studies dissected various domains of CBF
involved in DNA binding and transcription activation, this
prompted us to investigate whether speciﬁc domain of CBF
could contribute to the regulation of cell cycle. To do this,
as described herein, we expressed a truncated CBF-B,
Bdbd, lacking a transcription activation domain but contain-
ing a DNA-binding domain in various human and mouse
cells. Bdbd formed a CBF–DNA complex that lacked one
transcription activation domain. Our results showed that
expression of Bdbd in various cell lines resulted in cell
cycle arrest speciﬁcally at G2/M phase. Gene expression
analysis showed that Bdbd inhibited transcription activation
of Cyclin B1, Aurora A, and CDK1 genes, which all are
required for cell cycle progression at G2/M phase. Chromatin
immunoprecipitation analysis demonstrated that Bdbd
primarily inhibited recruitment of TATA-binding protein to
both cellular Cyclin B1 and Aurora A promoters. Together,
our study provided evidence that the CBF-B activation
domain controls cell cycle progression at G2/M phase, and
plays an essential role in transcription activation of Cyclin
B1 and Aurora A genes, two key regulators for G2/M
progression.
MATERIALS AND METHODS
Cell lines
The HeLa tet-off, Saos-2 tet-off and U2 OS tet-on cell lines
were purchased from BD Biosciences Clontech and main-
tained as instructed. The NIH 3T3 tet-off cell line was estab-
lished and maintained as reported previously (19). HeLa and
Saos-2 cells were maintained in DMEM supplemented with
10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin and 100 mg/ml G418.
For NIH 3T3 cells, calf serum instead of FBS and
200 mg/ml G418 were used. U2 OS cells were maintained
in a culture medium containing 90% McCoy’s 5A medium,
10% FBS, 4 mM L-glutamine, 200 mg/ml G418, 4.5 g/l glu-
cose, 10 mM HEPES, 1 mM sodium pyruvate and 0.2 U/ml
bovine insulin. The human embryonic kidney 293 IQ cell line
was purchased from Microbix Biosystems, and was used
for the development and ampliﬁcation of recombinant ade-
noviruses. The cells were maintained in the same medium
where HeLa cells were maintained in with the exception of
150 mg/ml hygromycin instead of 100 mg/ml G418. All the
cells were maintained in an incubator with 5% CO2.
Recombinant adenoviral expression vector and virus
The recombinant adenoviral expression vector was con-
structed by using the Adeno-X Tet-Off Expression Systems
(BD Biosciences Clontech). First, EcoRV/XbaI-restricted
gene fragments of FLAG-tagged CBF-B (Bwt) CBF-Bmut
(Bmut), and CBF-Bdbd (Bdbd) were generated from their
parental plasmids (pTRE-ﬂagB, pTRE-ﬂagBmut and pTRE-
ﬂagBdbd, respectively) (9,19). Each gene was cloned into
the shuttle vector pTRE-Shuttle2. A Tet-responsive expres-
sion cassette was excised from the recombinant shuttle
vector by PI-SceI/I-CeuI digestion and then cloned into the
replication-incompetent (E1/E3-deleted) Adeno-X viral
DNA to form a recombinant adenoviral expression vector.
Two such vectors, Ad-Bwt and Ad-Bdbd, were generated,
transformed and ampliﬁed in HB101. To make the recombi-
nant adenoviruses, each expression vector was linearized by
PacI digestion and transfected into E1-complementing 293
IQ cells. Ampliﬁcation was achieved by sequential infection
into the same cell line. The titer of the ﬁnal virus stocks at a
level of 8 · 10
7 pfu/ml was determined by following the
instructions in the manual of BD Biosciences Clontech. To
express the interested genes, the recombinant adenoviruses
were used to infect the tet-on or tet-off cells with or without
the addition of Tc or doxycycline. Unless otherwise indi-
cated, an MOI (multiplicity of infection) of 1:3 (three plaque
forming units of virus per cell, an equivalent of 25 ml stock)
was used for experiments in this study.
Synchronization, BrdU labeling and cell cycle analysis
HeLa cell synchronization at G1/S phase was achieved by
using a double thymidine block (22). Brieﬂy, the cells were
incubated with 2 mM thymidine for 18 h for the ﬁrst block,
released for 9 h after the thymidine was washed out, and
then incubated with thymidine at the same concentration
for 14 h for the second block. The cells were released by
washing out the thymidine and analyzed for cell cycle pro-
gression by ﬂow cytometry as described previously (19).
For S phase analysis, cells were labeled with BrdU by
using a FLUOS Kit (Roche Applied Science) as described
in the manufacturer’s protocol. Flow cytometry analyses
were performed with a FACS Calibur (BD Biosciences)
using the Cell Quest Pro software program.
Detection of CBF-B polypeptides in cell extracts and
after immunoprecipitation
To detect adenoviral mediated CBF-B expression, HeLa cells
at 22 h in six-well plates after adenovirus infection were
washed twice with PBS, and were lysed in 80 mlo f
1· SDS gel loading buffer (50 mM Tris–HC1, pH 6.8, 2%
SDS, 10% glycerol and 0.1% bromophenol blue). About
15 mg of each cell extracts were separated using SDS–
PAGE and then analyzed by western blotting using an anti-
CBF-B monoclonal antibody (Santa Cruz Biotech).
To determine the association of cellular CBF-A/CBF-C
heterodimer with Bdbd, whole cell extracts of Ad-Bdbd
infected HeLa cells were prepared by lysing the cells in a
buffer containing 150 mM NaCl, 1% NP-40 and 50 mM
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CBF-A antibody or IgG as a control at 4 C for 1.5 h, and then
precipitated with protein A–Sepharose 6B resin (Amersham
Biosciences). The resin bound proteins were eluted with
SDS gel loading buffer, and were separated by SDS–PAGE
followed by western blotting using an anti-CBF-B
monoclonal antibody.
Plasmids and transfection
A DNA fragment between  177 and +268 of human Aurora
A gene was isolated by genomic PCR and was cloned
between the SacI and XhoI sites of the pGL3-basic vector
to generate wild-type Aurora A promoter–reporter construct
( 177/+268). Single nucleotide mutation in each CCAAT
motif of the wild-type construct was introduced by two-step
PCR method (9) to generate Mt I, Mt II, and Mt I and II
constructs, as indicated in Figure 8D. These constructs were
transfected into mouse ﬁbroblast NIH3T3 cells by using the
LipofectAMINE reagent (Invitrogen), and expression of the
luciferase gene was measured as described previously (9).
DNA-binding assay
Cultured cells in 60 mm plates were ﬁrst washed twice with
PBS and then lysed in 400 ml of buffer consisting of 150 mM
NaCl, 50 mM Tris–HC1, pH 8.0 and 1% NP-40. Lysis was
performed for 30 min with occasional shaking at 4 C. The
cellular extract was obtained by high-speed centrifugation
of the lysates in a microcentrifuge. In each DNA-binding
assay reaction, 3 ml of the extract was used. The DNA-
binding assay method was described previously (23).
RNA isolation and northern blot analysis
Total RNA was isolated from 2 · 10
6 cultured cells by using
an RNeasy Mini Kit (Qiagen). RNA (10 mg) from each
sample was used for northern blot analysis as described
previously (19). After the analysis, the signal intensity of
the radioactive bands in the blot was quantiﬁed by using a
Phosphorimager in combination with the use of an image
analysis software ImageQuant 5.2 (Molecular Dynamics).
For each band, the mean intensity value and the standard
deviation for three independent experiments were calculated.
The Cyclin E1 (207–697 nt), CDK1 (216–652 nt), Cyclin D1
(311–731 nt) and FOXM1 (1206–1770 nt) cDNA probes
were obtained by PCR ampliﬁcation from cDNA clones,
which were purchased from either Harvard Institute of Pro-
teomics (Cyclin E1 and CDK1) or American Tissue Culture
Center (Cyclin D1). The cDNA clone for FOXM1 was a
gift from Dr R.H. Costa (24). The Cyclin B1 (800–1036 nt)
and the thymidine kinase I, TK1 (570–979 nt) cDNA probes
were generated by RT–PCR ampliﬁcation using total RNAs
of HeLa cells. The probe for Aurora kinase A (186–
1038 nt) was isolated by HindIII/EcoRI digestion from a
GFP-Aurora A construct (3). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) probe was isolated by EcoRI and
HindIII digestion of pTRI-GAPDH plasmid (Ambion).
Immunofluorescence analysis
HeLa cells grown on cover slips were ﬁxed with 4%
formaldehyde in PEM buffer (80 mM potassium–PIPES,
pH 6.8, 5 mM EGTA, pH 7.0 and 2 mM MgCl2) for
30 min on ice; permeabilized with 0.5% Triton X-100 in
the PEM buffer for 30 min at room temperature. After
incubation for another 30 min with a blocking solution (1%
BSA, 20 mM Tris–HCl, pH 7.4, 137 mM NaCl and 0.1%
Tween-20), the cells were incubated for 1 h each with the
primary antibody anti-phosphoserine 10-histone H3 (Upstate)
and an Alexa Fluor 488-conjugated secondary antibody
(Molecular Probes). The DNA of the cells was counterstained
with DAPI (20 mg/ml) in the blocking solution. Finally, a
ProLong Antifade kit (Molecular Probes) was used to
complete the mounting of the cover slips. The staining was
visualized under a Leica DMR microscope and the ﬂuores-
cent images were acquired by using the MetaMorph software
program (Universal Imaging).
Chromatin immunoprecipitation analysis
The chromatin immunoprecipitation (ChIP) was performed as
described previously (25). Brieﬂy,  10
7 HeLa cells were
incubated with formaldehyde for 10 min to cross-link the
chromatin DNA with bound proteins. Cross-linking was
stopped by the addition of glycine to a 125 mM ﬁnal concen-
tration. The cells were then washed, lysed and sonicated to
produce an average chromatin DNA fragment length of
0.5–1 kb. The lysis buffer consists of 5mM PIPES, pH 8.0,
85 mM KCl, 0.5% Igepal CA-630, 10 mg/ml aprotinin,
10 mg/ml leupeptin and 1 mM PMSF. The cell lysate contain-
ing chromatin DNAs was precleared with 20 ml of packed
protein A/G–agarose at 4 C for 2 h. Then, the chromatin
DNAs were incubated and precipitated with each of poly-
clonal antibodies against E2F3, E2F4 and TBP (Santa Cruz
Biotech), CBF-A (25) and rabbit IgG as a control. The
immunoprecipitation buffer consists of 0.01% SDS, 1.1%
Triton X-100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM
Tris–HCl, pH 8.1, 10 mg/ml aprotinin, 10 mg/ml leupeptin
and 1 mM PMSF. In the end, the precipitated chromatin
DNAs were extracted after reverse cross-linking and were
used in either regular or real-time PCRs to detect the pro-
moter DNA regions of speciﬁc genes. Ten percent of chro-
matin DNA before each immunoprecipitation was utilized
to isolate DNA by reverse cross-linking and extraction,
which was subsequently used as a source for input DNA in
each PCR. The PCR primers for each speciﬁc promoter are
listed in Supplementary Table S1.
Real-time PCRs with a SYBR Green approach were
performed to quantify ChIP DNAs corresponding to the
promoters of Cyclin B1, Aurora A, and TK1 genes. Primers
for these PCRs were designed by using Primer Express 2.0
(Applied Biosystems). The PCRs were set-up in optical 96-
well plates and performed in 20 ml of mixtures containing
1· SYBR Green Mix (Applied Biosystems), 1/100 fraction
of the ChIP-enriched DNA and 100 nM primers. A series
of dilutions of input DNAs were used in PCRs to determine
a standard curve for each individual pair of primers. PCRs
using ChIP DNAs precipitated with rabbit IgG were run for
the purpose of background subtraction. The plates were
read in an ABI Prism 7900HT real-time PCR instrument.
The amount of ChIP DNAs, as immunoprecipitated by anti-
bodies against different transcription factors, was calculated
by normalizing to the values of input material in the linear
range of PCR cycles. For each antibody, three independent
6274 Nucleic Acids Research, 2006, Vol. 34, No. 21ChIP assay were performed to isolate ChIP DNAs, which
were then quantiﬁed using real-time PCR.
RESULTS
Expression of a full-length CBF-B, Bwt, and a truncated
CBF-B, Bdbd, under the control of a tetracycline-
inducible adenoviral vector
We used a tetracycline (Tc)-regulated adenoviral vector to
express each of the full-length CBF-B (Bwt) and truncated
CBF-B (Bdbd) polypeptides in mammalian cells. Bdbd con-
sists of 96 C-terminal amino acids containing a DNA-binding
domain. Each of the CBF-B polypeptides was constructed as
a fusion protein with the FLAG epitope (Figure 1A). Recom-
binant adenoviruses Ad-Bwt and Ad-Bdbd were used to
infect HeLa cells expressing a tet-off activator, which induces
the expression of CBF-B polypeptide in the absence but not
the presence of Tc. Expression of both CBF-B polypeptides
was detected by using western blot with an anti-CBF-B anti-
body. Both Bwt and Bdbd were expressed at a comparable
level in HeLa cells in the absence but not the presence of
Tc (Figure 1B). The cellular or endogenous CBF-B was
also detected, as represented by the faint band just below
that for Bwt. This experiment showed that each of Bwt and
Bdbd polypeptides was overexpressed  10 times more than
that of cellular CBF-B.
Previously, we demonstrated that Bwt was associated with
cellular CBF-A/CBF-C complex and formed a DNA–protein
complex with CCAAT motif (26). To determine the interac-
tion of Bdbd with cellular CBF-A/CBF-C complex, cellular
extracts prepared from HeLa cells infected with Ad-Bdbd
in the presence and absence of Tc were immunoprecipitated
with anti-CBF-A antibody or rabbit IgG as a control. The
immunoprecipitated complex was analyzed by western blot-
ting using an anti-CBF-B antibody. This showed that Bdbd
was precipitated with anti-CBF-A antibody in cell extracts
in the absence of Tc (Figure 1C). In contrast, cellular CBF-
B was precipitated with anti-CBF-A antibody in cell extracts
in the presence of Tc. This indicated that similar to cellular
CBF-B, Bdbd was associated with cellular CBF-A/CBF-C
complex. Since no cellular CBF-B was detectable in the
immunoprecipitate containing Bdbd, it was suggested that
cellular CBF-A/CBF-C complex was exclusively associated
with Bdbd in HeLa cells expressing Bdbd. This was possibly
due to complete displacement of cellular CBF-B from
CBF-A/CBF-C complex by Bdbd.
The HeLa cell extracts were also monitored for
CBF-binding activity. This showed that the expression of
Bwt in the absence of Tc did not signiﬁcantly change the
cellular CBF-binding activity (Figure 2A). However, expres-
sion of Bdbd in the absence of Tc changed the mobility of the
cellular CBF–DNA complex by forming a faster moving
DNA–protein complex. An anti-FLAG antibody supershifted
the faster moving complex, indicating that the complex con-
tained Bdbd (data not shown). We interpreted the change in
mobility as being a result of the smaller size of Bdbd,
which displaced the larger size cellular CBF-B from CBF
complex. Consistent with the co-immunoprecipitation experi-
ment, there was an indication of complete displacement of
CBF-B by Bdbd in HeLa cells expressing Bdbd (MOI 1:3).
DNA-binding analysis of cell extracts prepared at various
time points after Ad-Bdbd infection (MOI 1:1.5) showed
Figure 1. Expression of full-length and truncated CBF-B in HeLa cells and
association of the truncated CBF-B with cellular CBF-A. (A) A full-length
(amino acids 2–341) CBF-B (Bwt) containing both transcription activation
and DNA-binding domains, and a truncated version (amino acids 240–336) of
CBF-B (Bdbd) lacking the activation domain were cloned in fusion with
FLAG into a Tc-induced adenoviral expression system. (B) After infection
with the recombinant adenovirus, HeLa cells in the presence or absence of Tc
were lysed to prepare whole cell extracts, which were analyzed by western
blotting with an anti-CBF-B antibody to detect Bwt (41 kDa) and Bdbd
(14 kDa). (C) Ad-Bdbd infected HeLa cells in the presence or absence of Tc
were lysed to prepare whole cell extracts and an anti-CBF-A antibody or IgG
was used to carry out an immunoprecipitation experiment. The immuno-
precipitated complex was then subjected to western blotting with an anti-
CBF-B antibody, which detected co-immunoprecipitated Bdbd in the absence
of Tc, but cellular CBF-B in the presence of Tc.
Figure 2. DNA-binding activity of CBF in HeLa cells expressing Bwt or
Bdbd. (A) Whole cell extracts from the recombinant adenovirus-infected
HeLa cells (MOI 1:3) in the presence or absence of Tc were used for the
DNA-binding assay. Expression of Bwt ( Tc) slightly increased DNA-
binding activity of CBF. Expression of Bdbd ( Tc) competed out the
endogenous CBF-B (Bwt) complex completely and formed a CBF complex
containing Bdbd. (B) The adenovirus Ad-Bdbd infected HeLa cells (MOI
1:1.5) in the absence of Tc were collected at various time points after the
infection and used in a DNA-binding assay to monitor formation of the
subshifted Bdbd–DNA complex. The results showed that the maximum
amount of the Bdbd–DNA complex was formed from 12 to 16 h after the
infection with disappearance of the cellular CBF–DNA (Bwt–DNA) complex.
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reached its maximum amount at 12–16 h of infection
(Figure 2B).
Expression of Bdbd inhibits cell cycle progression
Infection of HeLa cells with Ad-Bwt did not inhibit cell pro-
liferation in the absence of Tc (Supplementary Table S2). In
contrast, infection of HeLa cells with Ad-Bdbd greatly inhib-
ited cell proliferation in the absence of Tc. This indicated that
expression of Bdbd inhibited cell proliferation. To determine
the cell cycle distribution proﬁle of Bdbd-expressing cells,
the HeLa cells were analyzed by using ﬂow cytometry at
various time points after adenoviral infection (Figure 3A).
Expression of Bdbd resulted in a time-dependent increase
in the percentage of cells at G2/M phase. Speciﬁcally, the
data showed that the cell cycle distribution of the HeLa
cells after 24 h of infection with Ad-Bdbd in the presence
of Tc was 52% at G1, 19% at S and 27% at G2/M. In contrast,
the cell cycle distribution in the absence of Tc was 22% at
G1, 16% at S and 57% at G2/M. As a control, HeLa cells
infected with Ad-Bwt had a similar cell cycle distribution
between in the presence and absence of Tc. Interestingly,
dose-dependent effect of Bdbd was evident. HeLa cells
infected with increasing MOIs of Ad-Bdbd that resulted in
gradual increase of Bdbd level, also resulted in gradual
increase in the percentage of cells arrested at G2/M phase
(Supplementary Figure S1A–C). DNA-binding assay of
CBF at various Bdbd concentrations showed that the cellular
CBF (Bwt) was partially displaced by Bdbd at MOIs of 0.75
or 1.5. Thus, accumulation of cells at G2/M phase was
observed even when the cellular CBF was partially displaced
by Bdbd. In contrast, expression of Bwt had no effect on cell
cycle distribution (Supplementary Figure S1D). As another
control, a dominant-negative mutant of CBF-B (Bmut) that
inhibited DNA binding of CBF was also expressed in HeLa
cells using the adenoviral vector. This showed that the
expression of Bmut in the absence of tetracycline strongly
inhibited DNA binding of CBF and also resulted in retarda-
tion of cell growth (Supplementary Figure S2A–C), similarly
as observed in mouse ﬁbroblast cells in our previous publica-
tion (19). Flow cytometry analysis of Ad-Bmut infected cells
showed that no cell cycle distribution was changed with and
without expression of Bmut (Supplementary Figure S2D).
This suggests that Bmut inhibited HeLa cell proliferation
through growth arrest at multiple phases of cell cycle, simi-
larly as we have reported its effect on mouse ﬁbroblast
cells. This experiment supports the speciﬁc role of Bdbd at
G2/M phase of HeLa cells.
We analyzed HeLa cells by performing bromodeoxyuri-
dine (BrdU) labeling to determine S phase at various time
points after adenoviral infection (Supplementary Table S3).
At 12 and 16 h of Ad-Bdbd infection, a signiﬁcant percentage
of BrdU-labeled cells were detected both in the presence and
Figure 3. Cell-cycle analysis of HeLa cells expressing Bdbd or Bwt. (A) Flow cytometric analysis of HeLa cells at different time points after infection with
Ad-Bdbd or Ad-Bwt in the presence or absence of Tc. Fluorescence of propidium iodide-stained nuclei was used to measure DNA content. Expression of Bdbdi n
the absence of Tc led to the accumulation of cells at G2/M phase in a time-dependent manner. (B) Analysis of HeLa cells after 20 h of Ad-Bdbd infection with an
anti-phosphoserine 10-histone H3 antibody, which was detected by the Alexa 488 labeled secondary antibody. The nuclei were stained with DAPI. The merge
shows an overlay of green and blue fluorescence data.
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small percentage of BrdU-labeled cells were present in the
absence of Tc. This indicated that the expression of Bdbd
did not initially inhibit the HeLa cells at S phase. The loss
of HeLa cells at S phase at a later time point (24 h) was likely
caused by cell cycle arrest at G2/M phase.
The HeLa cells were also analyzed by immunostaining
with an antibody against phosphoserine 10-histone H3, a mar-
ker for G2 phase and mitotic cells (27). At 20 h of infection
with Ad-Bdbd, only  5% of the cells in the presence of Tc
were stained with the antibody, whereas >50% of the cells
in the absence of Tc were stained with the antibody
(Figure 3B). This supported the earlier observation that the
expression of Bdbd resulted in the arrest of cells at G2/M
phase.
To further analyze the effect of Bdbd expression on pro-
gression of the cell cycle, HeLa cells were ﬁrst synchronized
by using a double thymidine block and then analyzed by
using ﬂow cytometry (22). The cells were infected with
Ad-Bdbd when the ﬁrst release of the thymidine block
started, and then analyzed by ﬂow cytometry at various
time points after releasing the second block (Figure 4).
Most of the cells in the presence or absence of Tc were at
G1 phase at 0 h of release. At 3 h of release, a large percent-
age of the cells were at S phase, and at 6 and 9 h of release,
the percentage of cells at G2/M phase was increased both in
the presence and absence of Tc. At 12 h, most of the cells in
the presence of Tc completed mitosis and were at G1 phase;
in contrast, most of the cells in the absence of Tc were
arrested at G2/M phase along with some cells displaying
polyploidy. In comparison, analysis of Ad-Bwt infected
HeLa cells in the presence or absence of Tc showed similar
cell cycle progression pattern as that for Ad-Bdbd infected
cells in the presence of Tc (data not shown). These results
indicated that the expression of Bdbd speciﬁcally inhibited
the progression of normal cell cycle at G2/M phase. We
counted the mitotic cells by performing 40,60-diamidin-2-
phenylindone (DAPI) staining at various time points from 8
to 10 h of release (Figure 5A). This showed that at any
time point during this time range, <1% of the Bdbd-
expressing cells were mitotic compared with 8% of the
non-Bdbd-expressing cells (Figure 5B). We also analyzed
HeLa cells after incubating them with colchicine to arrest
the cells at prometaphase during the thymidine block and
Figure 4. Progression of the cell cycle after the expression of Bdbd in synchronized HeLa cells at G1/S phase. HeLa cells were synchronized by using a double
thymidine block and infected with Ad-Bdbd in the presence or absence of Tc. After release of the block, the cells were collected at different time points and then
analyzed by using flow cytometry, similarly as described in Figure 3A.
Figure 5. Effects of Bdbd expression on mitosis of HeLa cells. (A) Experimental design for mitotic cell count or prometaphase cell count after Bdbd expression.
Mitotic cell count (B) and prometaphase cell count (C) were performed after DAPI staining of Ad-Bdbd infected HeLa cells in the presence or absence of Tc. The
results showed that the expression of Bdbd significantly inhibited both mitotic and prometaphase cell counts. Arrows indicate mitotic or prometaphase cells.
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cells were stained with DAPI at 11 h of release from the
second thymidine block. About 40% of the cells without
Bdbd expression were at prometaphase (Figure 5B). In con-
trast, only 5% of the cells with Bdbd expression were at pro-
metaphase. This suggested that the expression of Bdbd
inhibits the entry of the cells into mitosis and arrests cells
at G2 phase.
To determine whether the expression of Bdbd has a similar
effect in cells other than HeLa cells, we expressed Bdbd in
two human osteosarcoma cell lines, Saos-2 and U2 OS, and
the mouse ﬁbroblast line NIH 3T3 (Figure 6). Saos-2 and
NIH 3T3 constitutively expressed the tet-off activator.
Thus, as in HeLa cells, Bdbd was expressed in the absence
but not in the presence of Tc in these cell lines. In contrast,
U2 OS constitutively expressed the tet-on activator, which
induced Bdbd expression in the presence but not in the
absence of Tc. We infected each of these cell lines with
Ad-Bdbd and grew them in the presence and absence of
Tc. At 48 h after infection, cell extracts were prepared to
determine the level of CBF-binding activity. We found a
Bdbd-speciﬁc DNA–protein complex was observed in all of
the cell extracts only when Bdbd expression was induced
(Figure 6A). In U2 OS cells in the presence of Tc, only
Bdbd-speciﬁc DNA–protein complex was observed, indicat-
ing that Bdbd completely displaced cellular CBF-B. In both
NIH 3T3 and Saos-2 cells in the absence of Tc, a Bdbd–
DNA complex was formed along with a residual cellular
Bwt–DNA complex. The results indicated that Bdbd did not
completely displace cellular CBF-B in these two cell lines.
To determine the cause for partial displacement of CBF
complex by Bdbd, we compared expression of Bdbd polypep-
tide in HeLa, U2 OS, NIH3T3 and Saos-2 by western blot
(Figure 6B). This showed that a low quantity of Bdbd was
expressed in Saos-2 cells compared with the other cell
lines. Quantiﬁcation of the western blot showed that Bdbd
was expressed 2.3-, 3- and 3.7-fold more in NIH3T3, HeLa
and U2 OS cells, respectively, in comparison with its expres-
sion in Saos-2 cells. This suggests that the partial displace-
ment of CBF complex in Saos-2 cells is due to low
quantity of Bdbd expression. The partial displacement of
CBF complex in NIH3T3 cells could also be due to lower
level of Bdbd in comparison to HeLa and U2 OS cells. How-
ever, we cannot rule out a possibility that other parameters
such as secondary modiﬁcations might play a role in the
interactions among CBF subunits and caused variation at
the level of displacement by Bdbd in different cell lines.
Despite this difference in displacement of cellular CBF-B,
analyses of these three cell lines by using ﬂow cytometry
showed that the expression of Bdbd resulted in an increase
in the percentage of cells at G2/M phase in each cell line
(Figure 6C). Consistent with this observation, expression of
Bdbd also inhibited proliferation of each cell line (Supple-
mentary Table S2). As a control, expression of Bwt had no
effect on cell cycle distribution in any of the cell lines (Sup-
plementary Figure S3). Thus, we concluded that expression
of Bdbd inhibits the proliferation of these cells and arrests
them at G2/M phase.
Expression of Bdbd suppresses transcription activation
at G2/M phase
As multiple CBF-binding sites are present in the promoters
of several genes that are activated at G2/M phase [(7–11);
Supplementary Table S4], we examined the expression of
some of these genes during cell cycle progression after
Figure 6. Expression of Bdbd in various cell lines caused arrest at G2/M phase. (A) DNA binding of CBF after the expression of Bdbd in various cell lines.
Whole cell extracts were prepared at 48 h after infection with Ad-Bdbd and used in a DNA-binding assay. (B) Flow cytometric analysis of various cell lines at
48 h after infection with Ad-Bdbd in the presence or absence of Tc. Expression of Bdbd was induced in the absence of Tc in NIH 3T3 and Saos-2 cells, whereas it
was induced in the presence of doxycycline in U2 OS cells. (C) The MOIs used were 1:3 for U2 OS cells, 1:6 for NIH 3T3 cells and 1:9 for Saos-2 cells.
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blot analysis showed that the expression of Cyclin B1 and
Aurora A is activated at 8 h of release, consistent with previ-
ously published observations (3,4). Interestingly, expression
of Bdbd strongly inhibited the transcription activation of
Aurora A and Cyclin B1 at 8 and 9 h of release of the second
thymidine block (Figure 7A). Expression of Bdbd also
reduced the activation of CDK1, and only slightly reduced
the expression of FOXM1 and Cyclin D1, but did not alter
the expression of TK1 and GAPDH. Quantiﬁcation of the
northern blot showed that Bdbd caused the fold inhibition
of gene expression at 9 h time point approximately 3.1, 2.6,
2.1, 1.5 and 1.5 for Aurora A, Cyclin B1, CDK1, FOXM1 and
Cyclin D1, respectively (Table 1). As a control, expression of
Bwt in the absence of Tc had little effect on gene expression
(Figure 7B). Quantiﬁcation data for the northern blot at 9 h
time point showed that the expression of Bwt resulted in
1.26 ± 0.16 fold increase of Aurora A but no change of Cyclin
B1, CDK1 and TK1 genes expression. Taken together these
results demonstrated that the expression of Bdbd-inhibited
transcription activation of Cyclin B1, Aurora A and CDK1
at late S and G2/M phases. As the cell cycle arrest occurred
speciﬁcally at G2/M phase, we did not extensively examine
the impact of Bdbd on the expression of G1/S genes. How-
ever, we did analyze the expression of one G1/S gene Cyclin
E1 after Bdbd expression, with a result showing no inhibition
of its expression at G1/S by Bdbd (Figure 7A).
Although the role of CBF binding in transcription of
Cyclin B1 and CDK1 promoters was studied in previous
reports (8), the function of CBF in transcription of the Aurora
A promoter is not known. The human Aurora A promoter
contains two CCAAT motifs, one of which is located on
the start of transcription, but it does not contain a TATA
box (29). Double-stranded oligonucleotides corresponding
to each CCAAT motifs were used in DNA-binding assay
with HeLa cell nuclear extracts (Figure 8A). This showed
that a DNA–protein complex formed with each labeled
oligonucleotide was supershifted with an anti-CBF-A anti-
body (Figure 8B). Each DNA–protein complex was competed
by excess wild-type oligonucleotide, but not by excess of
mutant oligonucleotide containing mutation of CCAAT to
CCAAA, indicating that both of the CCAAT motifs of
Aurora A promoter speciﬁcally interact with CBF
(Figure 8C). A promoter fragment containing  177 to +268
bp of human Aurora A gene was used to study the role of
CBF-binding sites in transcription activity. The wild-type
promoter DNA and three mutant promoter DNAs containing
mutations in the CBF-binding sites were constructed in a
luciferase reporter gene vector (Figure 8D). Activity of each
reporter construct was analyzed by transient transfection in
NIH 3T3 cells. This showed that mutations of distal (Mt I)
Figure 7. Analysis of the expression of various genes during cell cycle progression in HeLa cells after the expression of Bdbd or Bwt. The HeLa cells were
synchronized by using a double thymidine block, infected with Ad-Bdbd or Ad-Bwt, and then released from the block as described in Figure 4. The cells were
collected at different time points after the release and used to isolate total RNAs, which were analyzed by using northern blot analysis. Each lane contains 10 mg
of RNA. Analysis was carried out for RNA samples prepared from HeLa cells infected with Ad-Bdbd (A) or with Ad-Bwt (B) in the presence or absence of Tc.
This experiment was repeated three times specifically at 0 h, 8 h and 9 h time points.
Table 1. Quantification of the mRNA levels at 9 h time point of Figure 7A
Gene Relative band signal intensity of
detected genes (·10
5)
Fold inhibition
+Tc  Tc
Cyclin B1 45.39 ± 3.78 17.75 ± 1.19 2.56
Aurora A 7.28 ± 0.59 2.33 ± 0.18 3.12
CDC2 4.45 ± 0.36 2.14 ± 0.15 2.08
FOXM1 1.90 ± 0.17 1.24 ± 0.08 1.53
Cyclin D1 7.70 ± 0.46 5.25 ± 0.28 1.47
TK1 33.25 ± 2.30 32.96 ± 0.72 1.01
The band signal intensity representing the mRNA levels at 9 h time point in
Figure7AwasquantifiedbyusingaPhosphoimager.Datacollectedfromthree
independentexperimentswerenormalizedwiththevalueforGAPDHandused
for calculation of the mean and standard deviation. Fold inhibition of gene
expression was calculated as the ratio of the mean intensity value for without
Bdbd expression (+Tc) versus with Bdbd expression ( Tc).
Nucleic Acids Research, 2006, Vol. 34, No. 21 6279and proximal (Mt II) CCAAT motifs resulted in 2-and 6-fold
reduction of promoter activity, respectively. Mutations of
both CCAAT motifs (Mt I and Mt II) reduced promoter activ-
ity by 7-fold. This indicated that CBF binding to the Aurora
A promoter is required for its high level promoter activity.
Inhibition of TBP recruitment to Cyclin B1 and
Aurora A promoter by Bdbd
To determine whether CBF interacts with the cellular promo-
ters of the studied genes in HeLa cells, we performed chro-
matin immunoprecipitation (ChIP) experiments with the
anti-CBF-A antibody (Figure 9), which was used in earlier
experiment. This showed that CBF interacted with the cellu-
lar promoters of both Cyclin B1 and Aurora A genes. We also
performed the ChIP analysis at various time points after the
release of the double thymidine block. The results showed
that CBF interacted with the promoters at all of the time
points (supplementary Figure S2), indicating that CBF consti-
tutively occupied these promoters at all phases of the cell
cycle, consistent with previous publications (30–32). To
determine CBF occupancy after Bdbd expression, the ChIP
analysis was performed after infection of HeLa cells with
Ad-Bdbd in the presence and absence of Tc (Figure 9B and
C). This showed that anti-CBF-A antibody pulled down
equal amount of promoter DNAs with or without Tc. Since
CBF-A was exclusively associated with Bdbd in cells
expressing Bdbd, this indicated that CBF complex containing
Bdbd binds to promoter DNAs equally to CBF complex con-
taining full-length cellular CBF-B. As a control, Bdbd binds
to the promoter of TK1 gene. However, gene expression of
TK1 was not changed by Bdbd expression (Figure 7A). As
another control, Bdbd also binds to the promoter of XBP-1
gene, which is usually activated by endoplasmic reticulum
stress but expressed at a very low level in normal HeLa cells.
A recently published study demonstrated that a CBF-
binding site in the human Cyclin B1 promoter plays a role
in the recruitment of the E2F3 transcription factor during
the cell cycle (31). Another recent published study also
demonstrated that CBF binding to various promoters is
needed for the recruitment of a general transcription factor
and RNA polymerase II during inducible transcription (33).
To test these two possibilities, we examined the binding of
E2F3 and TATA-binding protein (TBP) to cellular promoters
Figure 8. The activity of Aurora A promoter is dependent on CBF binding to the two CCAAT motifs located within the promoter. (A) Oligonucleotide sequences
containing wild or mutant CCAAT box I or II. (B) DNA-binding assay for CBF binding to CCAAT box I or II. Radiolabeled oligonucleotide probes
corresponding to WT1 or WT2 and HeLa cell nuclear extracts were used for the assay. The DNA–protein complexes for both probes were supershifted by an anti-
CBF-B antibody, but not by IgG. (C) Competition of DNA–protein complexes by WT1 and WT2 but not by MT1 and MT2 unlabeled oligouncleotides of 50 or
100 times excess. (D) Wild-type CBF-binding sites in the Aurora A promoter is required for the promoter activity. Wild-type Aurora A promoter ( 177/+268)
and mutant promoters containing one or two mutated CCAAT boxes (from CCAAT to CCAAa) were constructed into a luciferase reporter vector. They
were transiently transfected into NIH 3T3 fibroblast cells to measure relative luciferase activity. This was done for a minimum of three times and in duplication
each time.
6280 Nucleic Acids Research, 2006, Vol. 34, No. 21using ChIP method after the expression of Bdbd. To examine
E2F3 binding, HeLa cells were synchronized by thymidine
block and infected with Ad-Bdbd similarly as described in
Figure 5A. The cells collected at 4 h of release from the
second thymidine block were used for ChIP experiment.
This showed that the expression of Bdbd, however, did not
change binding of E2F3 to cellular Cyclin B1 promoter
(Figure 10A). Similarly, binding of E2F4 to cellular Cyclin
B1 promoter either did not change after the expression of
Bdbd. This experiment also showed that neither E2F3 nor
E2F4 interacted with the proximal promoter of cellular
Aurora A gene.
Binding of TBP to both Cyclin B1 and Aurora A promoters
was examined by ChIP analysis in both synchronized and
unsynchronized HeLa cells. This showed that TBP has
equal occupancy to both Cyclin B1 and Aurora A promoters
at various time points after the release of the thymidine block
(Supplementary Figure S4). This indicated that similar to
CBF, TBP constitutively occupied these promoters irrespec-
tive of transcription activation during the cell cycle. Interest-
ingly, expression of Bdbd resulted in 2.3- and 2.6-fold
reduction of TBP binding to Cyclin B1 and Aurora A promot-
ers, respectively (Figure 10B and C). In contrast, TBP bind-
ing to TK1 promoter had slight reduction (1.18-fold) and its
binding to XBP-1 promoter was not changed by the expres-
sion of Bdbd. As a control for this experiment, TBP only
bound to the promoter region but not to a genomic region
far from the start of transcription. As another control, expres-
sion of TBP was detected by western blot after Ad-Bdbd
infection in the presence or absence of Tc. The results
showed that the expression of Bdbd had no effect on the pro-
tein level of TBP (Figure 10D). Altogether, this study demon-
strated that Bdbd signiﬁcantly inhibited TBP occupancy to
both Cyclin B1 and Aurora A promoters in HeLa cells.
DISCUSSION
Our study demonstrated that the expression of Bdbd contain-
ing a DNA-binding domain but lacking a transcription activa-
tion domain in various human and mouse cells inhibited cell
growth and speciﬁcally arrested cells at G2/M phase of the
cell cycle. The role of CBF in cell growth was previously
demonstrated in various studies in which DNA binding of
CBF was inhibited either by the expression of a dominant-
negative CBF-B subunit or by inactivation of the CBF-B
gene. Inhibition of DNA binding of CBF has been shown
to arrest cell growth at all phases of the cell cycle (19–21).
These studies indicated that CBF plays a role in the expres-
sion of genes required for cell cycle progression. However,
the speciﬁc function of CBF in each phase of the cell cycle
remains to be determined. In the present study, we unambi-
guously showed that the N-terminal activation domain of
CBF-B is speciﬁcally required for cell cycle progression at
G2/M phase.
Figure 9. Chromatin immunoprecipitation (ChIP) analysis of CBF binding to cellular promoters. (A) Schematic representation of Cyclin B1, Aurora A, TK1 and
XBP-1 promoters highlighting the CCAAT motif positions in relation to the transcription start site. Two side arrows indicate primer positions for ChIP
experiments. (B) The ChIP experiment was performed with a polyclonal anti-CBF-A antibody or rabbit IgG as a control using Ad-Bdbd infected HeLa cells in
the presence or absence of Tc. For input, PCR amplification was done using sonicated chromatin DNA before immunoprecipitation. The promoter of Cyclin E1
gene, which does not contain CBF-binding sites, was PCR amplified as a control. (C) The amount of ChIP DNAs corresponding to the promoters of Cyclin B1,
Aurora A and TK1 genes was quantified by real-time PCR with a SYBR Green approach. It is expressed as a percentage of the input DNAs used in
immunoprecipitation. Data presented in the histogram is the mean for three independent experiments. Standard deviations are displayed as error bars.
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progression at G2/M results from the inhibition of CBF-
dependent transcription activation of some essential G2/M
regulatory genes. Our results showed that Bdbd was associ-
ated with cellular CBF-A/CBF-C and formed a DNA–protein
complex similar to the complex formed with full-length
CBF-B. The difference between the two DNA–protein com-
plexes is that the one formed with full-length CBF-B contains
two activation domains provided by CBF-B and CBF-C,
whereas the one formed with Bdbd contains only one trans-
cription activation domain provided by CBF-C. Our previous
studies using an in vitro transcription system showed that
Bdbd, together with full-length CBF-A/CBF-C activated
transcription of various promoters, but the level of activation
was almost half of that by the full-length CBF-B subunit (23).
This indicated that the activation domain of CBF-B con-
tributes half of the CBF-dependent activation in vitro. From
this observation one would expect that Bdbd should inhibit
expression of any cellular genes, which promoters contain
CBF-binding site. In contrast, our results showed that Bdbd
inhibited expression of Cyclin B1 and Aurora A but not
TK1, although the promoters of all three genes interacted
with CBF which was not altered by Bdbd expression as
shown by ChIP analysis. This suggests that the activation
domain of CBF-B plays a speciﬁc role in transcription
activation of Cyclin B1 and Aurora A genes.
The gene expression analysis we performed during
progression of the cell cycle showed that Bdbd primarily
inhibited transcription activation of Cyclin B1, Aurora A
and CDK1, which occurred from late S to G2/M phase of
the cell cycle in HeLa cells. This also showed that Bdbd
modestly inhibited activation of FOXM1 and Cyclin D1,
but did not inhibit the expression of Cyclin E1 and TK1
(Figure 7A). Recent studies have shown that the inhibition
of expression of either Cyclin B1 or Aurora A leads to cell
cycle arrest at G2/M phase. The protein products of these
genes play important roles in entry into mitosis and chromo-
some segregation (3,4). Similarly, inhibition of FOXM1
expression also resulted in cell cycle arrest at G2/M phase
(34,35). Several studies demonstrated that the inhibition of
DNA binding of CBF resulted in decreased expression of
Cyclin A, CDC25C and topoisomerase IIa, whose expression
is also activated at late S and G2/M phase (19,21), suggesting
a possibility that Bdbd could also inhibit the expression of
these additional genes in HeLa cells. Altogether, this suggests
that the G2/M arrest by Bdbd is likely due to accumulative
effect of the inhibition of multiple genes expression required
for G2/M progression. Our gene expression analysis showed
that Bdbd did not inhibit the expression of Cyclin E1,
which is activated at G1/S phase. Our analysis, however,
did not extensively examine the expression of genes at
G1/S phase of the cell cycle. Since Bdbd did not inhibit
cell cycle progression at G1/S phase, we speculate that
Bdbd did not play a signiﬁcant role in the expression of
G1/S phase genes. In addition, previous study showed that
inactivation of CDK1 in human cells resulted in initial accu-
mulation at G2/M phase followed by increase of polyploidy
without entering into mitosis (36). This study interpreted
that the polyploidy without mitosis was developed due to
re-replication of chromosome. Since Bdbd also reduced the
expression of CDK1, which could partly explain the develop-
ment of polyploidy in Bdbd expressing cells.
Figure 10. Chromatin immunoprecipitation (ChIP) analysis of E2F3, E2F4 and TBP binding to cellular promoters. (A) The ChIP experiment was performed with
antibodies against E2F3 and E2F4 using Ad-Bdbd infected HeLa cells, which were synchronized and collected at 0 h of release similarly as described in Figure 4.
(B) The ChIP experiment was performed with an anti-TBP antibody using Ad-Bdbd infected HeLa cells. A non-promoter genomic region at 30 end of GRP78
gene was PCR amplified as a negative control. (C) The amount of ChIP DNAs was quantified and presented in the same way as for Figure 9C. (D) Analysis of
TBP protein level in Ad-Bdbd infected HeLa cells in the presence or absence of Tc. Whole cell extracts were made and western blot analysis was performed with
both anti-TBP and anti-b-actin antibodies. Detected amount of b-actin served as an internal control.
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to Aurora A promoter is needed for Aurora A promoter
activity. Furthermore, ChIP analysis demonstrated that
CBF constitutively occupied cellular Aurora A promoter at
various stages of the cell cycle, indicating that CBF directly
regulates transcription of Aurora A gene. Similarly, CBF also
constitutively occupied cellular Cyclin B1 promoter, indica-
ting that the activation of Cyclin B1 and Aurora A genes
at G2/M is not due to increase in binding of CBF to these
promoters.
A recently published promoter analysis demonstrated that
CBF-binding site in CDK1 and Cyclin B1 promoters plays
a role in the recruitment of the E2F3 transcription factor
speciﬁcally at G2/M phase of the cell cycle (31). Although
the function of the E2F activators (E2F1, E2F2 and E2F3)
has been known to be a speciﬁc activator for S phase-speciﬁc
genes, the function of these activators in transcription at
G2/M phase has also been revealed in several publications
(30,31,37). Our ChIP analysis showed that E2F3 interacts
with cellular Cyclin B1 but not with Aurora A promoter.
Currently it is not known whether E2F3 binds to Aurora A
promoter. It is possible that E2F3-binding site is located
far from CBF-binding sites in the Aurora A promoter; thus,
it could not be detected by our ChIP analysis detecting
only proximal promoter region. Nonetheless, we compared
E2F3 binding to Cyclin B1 promoter with or without Bdbd
expression. This showed that Bdbd did not change E2F3
binding to Cyclin B1 promoter. In contrast, Bdbd inhibited
TBP binding to Cyclin B1 promoter. Similarly, Bdbd also
inhibited TBP binding to Aurora A promoter. As a control,
Bdbd caused slight inhibition of TBP binding to TK1 pro-
moter and no inhibition to XBP-1 promoter, even though
CBF also binds to both promoters. This indicated that
Bdbd primarily inhibited TBP binding to Cyclin B1 and
Aurora A promoters. Since Bdbd did not inhibit DNA binding
of CBF, it is possible that only DNA binding of CBF is sufﬁ-
cient for E2F3 recruitment to Cyclin B1 promoter, whereas
both DNA binding and activation domains of CBF are
required for TBP binding to Cyclin B1 and Aurora A
promoters.
In this regard, a recent publication demonstrated that
CBF binding to an osteoclast differentiation factor (ODF)
promoter is essential for activation of the ODF gene in the
presence of vitamin D3, parathyroid hormone and prosta-
glandin E (33). Interestingly, this publication showed that
CBF is also needed for the recruitment of TBP and RNA
polymerase II to the cellular ODF promoter. Thus, the authors
of this publication hypothesized that CBF regulates inducible
transcription through recruitment of general transcription
factor and RNA polymerase II. Similarly, CBF binding to a
human g-globin promoter is also required for the recruitment
of TBP and RNA polymerase II to the promoter in adult
erythroblasts but not in embryonic erythroid cells (38). This
suggested a possibility that CBF controls inducible or devel-
opmentally speciﬁc transcription of various genes through
recruitment of TBP and other general transcription factors.
Based on our present study, we propose that the activation
domain of CBF-B controls such recruitment of TBP and
possibly other general transcription factors to the cellular
promoters. However, we do not consider this function as a
general property of CBF, since Bdbd signiﬁcantly inhibited
TBP recruitment to Cyclin B1 and Aurora A promoters but
not to TK1 and XBP-1 promoters which also interacted
with CBF.
To test whether CBF directly interacts with TBP, we had
analyzed a puriﬁed CBF-B complex from HeLa cells using
immunoafﬁnity method (26). Our previous analysis of
CBF-B complex by mass spectrometry showed that CBF-B
associated with CBF-A, CBF-C, and P32 but no TBP. Now
we also analyzed the puriﬁed CBF-B complex by western
blot method using anti-TBP antibody. This also showed that
no TBP was associated with the CBF-B complex (data not
shown). These results indicated that TBP does not directly
interact with CBF in HeLa cells. Our study is also in agree-
ment with a previous publication that showed CBF does not
interact with TBP in a human g-globin promoter, although
CBF is required for TBP recruitment to the promoter (38).
We speculate that the activation domain of CBF regulates
the recruitment of TBP through an indirect mechanism,
possibly required another factor that binds to Cyclin B1 and
Aurora A promoters.
As mentioned in Introduction, comparative genomic
analysis showed that a conserved promoter element consis-
ting of CBF-binding site and two other elements, cell
cycle-dependent element (CDE) and cell cycle homology
region (CHR) is found in several human promoters that are
speciﬁcally activated at G2/M phase of cell cycle (31). How-
ever, nuclear protein(s) that bind to CDE or CHR have not
been identiﬁed. We speculate that CBF could cooperate
with CDE- or CHR-binding protein(s) to recruit TBP and to
activate transcription at G2/M phase. Future study of CDE-
and CHR-binding protein(s) could elucidate speciﬁc role of
the CBF activation domain in transcription activation at
G2/M phase.
It is also possible that this speciﬁc function of CBF is
dependent on promoter architecture. Both Cyclin B1 and
Aurora A promoters contain CBF-binding sites, which are
located very close to the start of transcription. However,
none of these two promoters contains putative TATA box,
the typical TBP-binding site. This suggests that TBP indi-
rectly binds to Cyclin B1 and Aurora A promoters possibly
through interaction with TBP-associated factors, TAFs,
which are known to interact directly with TATA-less promo-
ters (39). We speculate that due to close proximity of CBF
binding to the start of transcription, the activation domain
of CBF-B could regulate such indirect binding of TBP to
the promoter DNAs. In this regard, it has been reported that
CBF interacts with TBP and several TAFs, components of
TFIID complex in vitro (40), suggesting that the activation
domain of CBF-B could directly interact with TFIID complex
and thus stabilize its binding to the cellular Cyclin B1 and
Aurora A promoters.
In summary, our study demonstrated that the activation
domain of CBF-B is speciﬁcally needed for the cell cycle
progression at G2/M phase, and it plays a vital role in the
cell cycle-dependent transcription activation of Cyclin B1
and Aurora A genes, which are very essential for cell cycle
progression at G2/M phase.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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